Lebanon, NH-based Adimab, Inc., a proveder of human antibody discovery and optimization platform, announced the closing of a Series D financing led by Google Ventures with participation by previous investors Polaris Ventures, SV Life Sciences, OrbiMed Advisors and Borealis Ventures.
The total amount of the financing was not disclosed.
Bill Maris of Google Ventures will join Adimab’s Board of Directors.
Commenting on the financing, Errik Anderson, Chief Operating Officer at Adimab, said: “Adimab reviewed multiple investment proposals but it was clear that Google Ventures immediately understood our value proposition – that a prolific discovery platform can drive even greater productivity when integrated with advanced computational tools.
“The continued support of our previous investor base is also testament to the strength of this proposition”.